louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05314075: Determination of Core Body Temperature in Parturient Warmed With Upper or Underbody Forced Air Cover (Bair Hugger)
Official title: Determination of Core Body Temperature in Parturient Warmed With Upper or Underbody Forced Air Cover (Bair Hugger)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cesarean Section
Keywords: Thermoregulation
Forced air warming
upper or lower body forced air cover
core body temperature
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
First posted: 2022-04-06
Enrollment: 130
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study is intended to calculate the core body temperature in patients who are having a Cesarean Section (C/S) and are kept warm with an Upper Body Forced Air Warming device (Bair Hugger) or underbody forced air warmer. These warming devices are approved and are a required item in many if not all surgical procedures. They are used daily throughout the hospital. The research question is: Where is the best place to position the warming blanket in pregnant mothers undergoing Cesarean section delivery. The researchers hope to compare post - operative core body temperatures in patients getting an Upper Body forced air device versus those getting an Underbody Body forced air warming device.


Eligibility criteria: Inclusion Criteria:

* Age =/\> 18 years
* Elective non-emergent C-section

Exclusion Criteria:

* BMI\<18/\>40
* Bleeding Disorders e.g. hemophilia, coagulation abnormality, clotting disorders, bleeding diathesis
* Perioperative hemorrhage \>1500ml
* Non-Singleton Pregnancies
* Complicated Pregnancy (e.g. Eclampsia, Pre-eclampsia)
* Conversion to Emergency C-section
* Endocrine Pathology- e.g. Thyroid Disease, Insulin Dependent Diabetes
* Inmates

Primary outcomes:
measure: Core body temperature
timeFrame: 1 hour post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
Study officials:
affiliation: Virginia Commonwealth University
name: Fatoumata Kromah, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06512675: Effects of an Exercise Program on Reaction Time and Mouse Accuracy in Esports Athletes
Official title: Effects of an Exercise Program on Reaction Time and Mouse Accuracy in Esports Athletes
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Quality of Life
Keywords: Exercise
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study is intended to evaluate the effects of an exercise program on the change of electronic sports (esports) athletes' reaction time and mouse click accuracy. The benefits of participation are directly related to exercise, and include improved thinking, performance, sleep, and quality of life.


Eligibility criteria: Inclusion Criteria:

1. University of Miami electronic sports (esports) club team members

Exclusion Criteria:

1. Non- University of Miami electronic sports (esports) club team members
2. Individuals who are not able to participate in a full body exercise program, whether due to injury or an underlying medical condition
3. Individuals who cannot comprehend basic instruction on exercise whether due to a cognitive impairment or language barrier (ie: non-English speaker).

Primary outcomes:
measure: Change in participants' physical reaction time
timeFrame: Baseline and up to 6 weeks after starting the program
measure: Change in percentage of participants' mouse click accuracy
timeFrame: Baseline and up to 6 weeks after starting the program
Secondary outcomes:
measure: Change in participants' number of target efficiency
timeFrame: Baseline and up to 6 weeks after starting the program
measure: Change in participants' clicks per second
timeFrame: Baseline and up to 6 weeks after starting the program
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Timothy Tiu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00682175: Metabolic Derangements in Acute Heart Failure Syndrome
Official title: Metabolic Derangements in Acute Heart Failure Syndrome
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Congestive Heart Failure
Keywords: Congestive Heart Failure
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2008-05-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult (age \> 18 yrs) patients admitted to the Heart Failure Intensive Care Unit (H22) with Acute Heart Failure Syndrome (AHFS) requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.

Brief summary: To determine the association of both neurohormonal and hemodynamic alterations associated with metabolic abnormalities in acute heart failure syndrome.


Eligibility criteria: Inclusion Criteria:

* Adult (age \> 18 yrs) patients admitted to the Heart Failure Intensive Care Unit (H22) with Acute Heart Failure Syndrome (AHFS) requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.

Exclusion Criteria:

* History of Congenital Heart Disease.
* Acute HF in the setting of acute myocardial infarction.
* Severe Anemia
* Patients listed for cardiac transplantation.
* Terminal Malignancy, AIDS or CNS disease.
* Concomitant sepsis, ARDS, trauma, aortic dissection, or pericardial tamponade

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: The Cleveland Clinic
name: George Sokos, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00645775: Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome
Official title: The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Metabolic Syndrome
Obesity
Dyslipidemia
Keywords: Weight loss
Antiobesity
Metabolic syndrome
Leptin
Lead sponsor: Gateway Health Alliance
Sponsor class: INDUSTRY
Collaborators: name: University of Yaounde
First posted: 2008-03-28
Enrollment: 102
Sex: ALL
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study investigated the use and efficacy of the seeds of African bush mango (Irvingia gabonensis)to control body weight, blood lipids and hormones in overweight and obese people.

Detailed description: To assess the effects of seeds of Irvingia gabonensis on body weight, fasting blood glucose, plasma total and LDL cholesterol in 102 overweight and obese participants.

The study was a 10 week randomized, double blind, placebo controlled design. participants were randomly divided into 2 groups of 51 participants each. Group 1 was the placebo group, while Group 2 was the active group. Each group received 2 daily doses of 125 mg (before meals) of either placebo or Irvingia gabonensis.

Weight as well as fasting blood was taken at baseline and at 4, 8 and 10 weeks. No major detary changes or exercises were suggested during the study period.

Eligibility criteria: Inclusion Criteria:

* BMI\>26

Exclusion Criteria:

* Diabetics Pregnant and lactating Participating in any other weight reducing program Smokers

Primary outcomes:
measure: Weight change
timeFrame: 10 weeks
Secondary outcomes:
measure: Change in blood lipids and hormone levels
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Yaounde
country: Cameroon
facility: Laboratory of Nutrition & Nutritional Biochemistry
state: Centre
Study officials:
affiliation: Gateway Health Alliances / University of Yaounde
name: Julius E Oben, PhD
role: STUDY_DIRECTOR
References:
citation: Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids Health Dis. 2009 Mar 2;8:7. doi: 10.1186/1476-511X-8-7.
Clinical trial NCT04254575: Understanding Daily Changes in BDD Risk Using Smartphones
Official title: Smartphone-based Digital Phenotyping to Detect High-risk Affect States in Body Dysmorphic Disorder (BDD)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Body Dysmorphic Disorders
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2020-02-05
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with a current primary diagnosis of body dysmorphic disorder (BDD) within the U.S.

Brief summary: Body dysmorphic disorder (BDD) is associated with high risk for suicide attempts (22-28%) and substance use disorders (49%), underscoring the importance of accurate, real-time risk detection in BDD. This study aims to use smartphone-based digital phenotyping to develop and validate unobtrusive, time-sensitive, and ecologically valid measures of key risk factors for suicide and substance misuse in BDD: negative affect states. As next steps, this research can be extended to detect risk transdiagnostically, with the goal of enabling just-in-time interventions to target suicide and substance misuse across psychiatric illnesses.


Eligibility criteria: Inclusion Criteria:

* Adults age \>=18
* Current primary diagnosis of BDD
* BDD severity \>= moderate
* Living in US
* English proficiency
* Owns an Android or iOS (Apple) smartphone
* Has regular Wifi-enabled internet access for data downloads

Primary outcomes:
measure: Self-reported anxiety intensity, rated from 1 (very slightly or not at all) to 5 (extremely)
timeFrame: 3 months
measure: Self-reported shame intensity, based on Positive and negative affect scale (PANAS) shame item, rated from 1 (very slightly or not at all) to 5 (extremely)
timeFrame: 3 months
measure: Self-reported negative affect intensity, based on Positive and negative affect scale (PANAS) negative affect items (averaged), rated from 1 (very slightly or not at all) to 5 (extremely)
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Hilary Weingarden, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02444975: The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST
Official title: The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Recurrent Urinary Tract Infection
Keywords: Urinary Tract Infections
Water intake
Lead sponsor: Danone Global Research & Innovation Center
Sponsor class: INDUSTRY
First posted: 2015-05-15
Enrollment: 140
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether increased water intake is effective in preventing episodes of uncomplicated urinary tract infections (UTI) in pre-menopausal women suffering from UTI recurrences.

Detailed description: This study aims to assess the effect of increased daily water intake on the frequency of clinical, recurrent urinary tract infections (UTI) among low drinking pre-menopausal women suffering from recurrent community-acquired UTI over 12 consecutive months of study product consumption. It is a prospective, single site, open-label, randomised controlled trial in two parallel groups:

* Control group: not changing their fluid intake habits
* Intervention group: provided with mineral water, fluid intake recommendations and regular hydration coaching support

The study population consists in pre-menopausal women diagnosed with recurrent UTIs and having a 'low drinker' profile.

The total number of randomized subjects in this study is estimated at 140. The study will include only women who are low-drinkers (\< 1.5 L fluids per day; urinary volume \< 1.2 L per day) since they are most likely to have a predisposition to UTIs due to infrequent voiding.

Eligibility criteria: Inclusion Criteria:

* At least 3 clinical recurrences of symptomatic UTI in the last 12 months
* Age ≥ 18 years

Exclusion Criteria:

* Incapacity / non-willingness to consume 1.5 L of drinking water per day on top of their usual consumption
* Women with history of UTI complications (pyelonephritis or other) in the last 12 months
* Subjects with interstitial cystitis
* Subjects with severe or uncontrolled organic disease, likely to interfere with the parameters of the study

Primary outcomes:
measure: Incidence of UTI
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sofia
country: Bulgaria
facility: Mc "Comac Medical"
Study officials:
References:
citation: Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, Lotan Y. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med. 2018 Nov 1;178(11):1509-1515. doi: 10.1001/jamainternmed.2018.4204.
Clinical trial NCT02139475: Factors Influencing Quality of Bowel Cleansing for Colonoscopy in Patients With Colorectal Cancer Surgery; Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Colorectal Cancer
Keywords: bowel cleansing, colorectal cancer surgery
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2014-05-15
Enrollment: 273
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing colonoscopy after colorectal cancer surgery

Brief summary: The aim of this study is to clarify the factors influencing quality of bowel cleansing for colonoscopy in patients with colorectal cancer surgery and confirm the adequate bowel cleaning method for patients with colorectal cancer surgery. Through this, ultimately in patients with a history of colorectal cancer who have high risk of colorectal cancer, it could be possible to detect cancerous lesions early and increase the survival rate.

This study is based on observational study Subjects are the patients with colorectal cancer surgery who visits the out patients clinic for follow-up colonoscopy The patient's medical records on the basis of information collected at the point of the colonoscopy performed Quality of bowel cleansing is calculated with the Boston bowel preparation scale Patient compliance and satisfaction are measured.


Eligibility criteria: Inclusion Criteria:

* age ≥ 20
* patients who underwent colorectal cancer surgery
* patients who underwent follow-up colonoscopy as a conventional medical procedures

Exclusion Criteria:

* age \< 20
* patients who have ileus or bowel obstruction
* patients in pregnant status
* Patients who did not consent to research

Primary outcomes:
measure: Boston bowel preparation scale (BBPS)
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance hospital
Study officials:
References:
Clinical trial NCT06984575: Relationship Between Intestinal Flora Changes and Hyperuricemia Under Chronic Psychological Stress
Official title: Relationship Between Intestinal Flora Changes and Hyperuricemia Under Chronic Psychological Stress
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyperuricemia
Lead sponsor: Shanghai 10th People's Hospital
Sponsor class: OTHER
First posted: 2025-05-22
Enrollment: 67
Sex: MALE
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Hyperuricemia patients and healthy controls

Brief summary: To clarify the mechanism of stress on the incidence of hyperuricemia

Detailed description: To clarify the differences in intestinal microorganisms and metabolism between healthy people and hyperuricemia patients and across different level of stress

Eligibility criteria: Inclusion Criteria:

1. Obtain the informed consent of the subjects before conducting any trial-related activities;
2. Males aged 18-69;
3. The hyperurcemia group must meet the diagnostic criteria of having blood uric acid \>420umol/L measured twice on an empty stomach on different days under a normal purine diet;

Exclusion Criteria:

- 1)Use of any uric acid-lowering drugs, anti-gout drugs, steroids, proton pump inhibitors, or non-steroidal anti-inflammatory drugs within one month before enrollment; 2)Use of any antibiotics, probiotics, or other drugs including traditional Chinese medicine within one month before enrollment; 3)Abnormal liver function, ALT and AST are more than 2.5 times the upper limit of normal; 4)Other diseases that affect glucose and lipid metabolism: hyperthyroidism, hypothyroidism, hypercortisolism, etc.

5)Chronic kidney disease or severe renal impairment, according to eGFR grading \<45mL/min/1.73m2; 6)Secondary hyperuricemia 7)Any gastrointestinal diseases

Primary outcomes:
measure: Phenotype differences in the gut microbiome by metagenomic sequencing.
timeFrame: Samples to be collected once per participant within 7 days of enrollment
measure: sequencing results of the fecal metabolome in the population
timeFrame: Samples to be collected once per participant within 7 days of enrollment
Secondary outcomes:
measure: Serum uric acid
timeFrame: Samples to be collected once per participant within 7 days of enrollment
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Tenth People's hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT06204575: Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism
Official title: Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atypical Parkinsonism
Dementia With Lewy Bodies
Multiple System Atrophy, MSA
Keywords: focused ultrasound
tremor
surgery
thalamotomy
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2024-01-12
Enrollment: 8
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients that underwent FUS VIM-thalamotomy and suffered from MSA or DLBD

Brief summary: The goal of this retrospective observational study is to describe the efficacy of focused ultrasound ventral-intermediate nucleus thalamotomy in patients with atypical parkinsonism.

* Is this treatment efficacious in patients with multiple system atrophy?
* Is this treatment efficacious in patients with diffuse Lewy Body Dementia? Data will be collected from patients charts.


Eligibility criteria: Inclusion Patients that underwent FUS ventral-intermediate nucleus thalamotomy Suffer from multiple system atrophy-Parkinsonian type (MSA-P) or dementia with Lewy bodies (DLBD).

-

Exclusion Criteria:

* Patients that did not underwent FUS ventral-intermediate nucleus thalamotomy
* Patients that underwent FUS ventral-intermediate nucleus thalamotomy and do not suffer from MSA or DLBD

Primary outcomes:
measure: Clinical Rating Scale for Tremor
timeFrame: baseline, pre-procedure, 1 month, 6 months and 1 year following procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
References:
Clinical trial NCT04459975: Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units
Official title: Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: on Occurrence of Acurate Kidney Injury During Intensive Care Unit
Abnormalities of Urinary Analysis
Keywords: Acurate Kidney Injury
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-07-07
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients supported in intensive care units for covid-19 infection

Brief summary: The actual COVID-19 epidemy is an unprecedented healthcare problem. Although acute respiratory distress syndrome is the main organ failure, acute kidney injury (AKI) has appeared to be more frequent and more severe than expected. Some data suggested a potential direct renal tropism of the virus, or undirect injury by "cytokine storm".

The aims of this study are:

1. To describe incidence, severity and mortality associated with AKI during covid-19 infection in ICU
2. To identify specific risk factors for AKI
3. To explore pathophysiologic mechanism of AKI during COVID-19 infection


Eligibility criteria: Inclusion Criteria:

* Confirmed COVID-19 infection (by qRT-PCR and/or TDM typical lesion)
* Needing intensive care

Exclusion Criteria:

* End Stage Renal Disease patients (with pre-existent dialysis)
* Intensive care support for less than 72h (transfer in conventional unit or death)

Primary outcomes:
measure: Primary endpoint is the incidence, the severity and the mortality associated with AKI during COVID-19 severe infection
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Intensive care units attached to the Hospices Civils de Lyon (HCL)
Study officials:
References: